Adalimumab with other therapy for early-stage lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding adalimumab to standard anti-cancer treatment can improve outcomes for people with non-small cell lung cancer that can be surgically removed. It aims to see if this combination is safe and effective before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have been diagnosed with stage II, IIIA, or some stage IIIB non-small cell lung cancer that can be surgically removed.
- You have not had prior systemic treatment for this lung cancer (like chemotherapy or targeted therapy).
- You have not received or plan to receive chest radiation or ablation therapy.
- You are willing to provide a tumor tissue sample for testing.
- You have adequate organ and blood function, and if applicable, agree to use contraception.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combined with other treatments for people with lung cancer that can be removed by surgery. It aims to see if the treatment shrinks tumors before surgery and improves outcomes.
This trial tests whether adding adebrelimab (an immunotherapy drug) to standard chemotherapy before surgery can shrink non-small cell lung cancer that can be removed. The goal is to improve the chance of successful surgery and reduce the risk of the cancer coming back.
This trial tests whether combining an immunotherapy drug (adebrelimab or retlirafusp alfa) with another drug (recaticimab) and chemotherapy helps shrink lung cancer before surgery. The goal is to see if this approach improves outcomes for people with resectable non-small cell lung cancer.
This trial tests a new drug, SHR-A2102, combined with other treatments for people with non-small cell lung cancer that can be removed with surgery. It aims to improve outcomes by using multiple therapies together.
This trial tests a combination of two drugs, SHR-A2102 and Adebrelimab, with or without other treatments, for people with advanced or metastatic non-small cell lung cancer that cannot be removed by surgery or cured with radiation. It aims to see if this approach can shrink tumors or slow the cancer's growth.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Hear when a new Resectable Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.